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Abstract
Previously, we have reported amyotrophic lateral sclerosis (ALS) families with multiple mutations in major ALS-associated genes. These
findings provided evidence for an oligogenic basis of ALS. In our present study, we screened a cohort of 755 sporadic ALS patients, 111
familial ALS patients (97 families), and 765 control subjects of Dutch descent for mutations in vesicle-associated membrane protein B
(VAPB). We have identified 1 novel VAPB mutation (p.V234I) in a familial ALS patient known to have a chromosome 9 open reading frame
72 (C9orf72) repeat expansion. This p.V234I mutation was absent in control subjects, located in a region with high evolutionary
conservation, and predicted to have damaging effects. Taken together, these findings provide additional evidence for an oligogenic basis of
ALS.
© 2012 Elsevier Inc.
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Amyotrophic lateral sclerosis (ALS) is a complex neurode-
generative disorder of upper and lower motor neurons. Re-
cently, we screened 97 families with familial ALS (FALS) for
mutations in TAR DNA-binding protein (TARDBP), fused in
sarcoma/translated in liposarcoma (FUS/TLS), superox-
ide dismutase-1 (SOD1), angiogenin (ANG), and chromo-
some 9 open reading frame 72 (C9orf72) (van Blitter-
swijk et al., 2012). In 5 of these families we identified
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Open access under the Elsevier OA license.multiple mutations, which is higher than one might ex-
pect on the basis of chance (p  1.57  107). We
emonstrated that C9orf72 repeat expansions were com-
ined with TARDBP, FUS/TLS, and SOD1 mutations, and
hat ANG mutations were also combined with TARDBP
nd FUS/TLS mutations. These findings supported an
ligogenic etiology of ALS.
In our cohort of FALS patients, we had not yet deter-
ined the mutation frequency of vesicle-associated mem-
rane protein B (VAPB). A mutation in VAPB (p.P56S) was
nitially reported in Brazilian families with motor neuron
isease (Nishimura et al., 2004). Families with VAPB mu-
ations demonstrate a wide range of phenotypes: their age at
nset varied from 25 to 55 years of age, their disease
rogression from 2 to 30 years, and they were diagnosed
ith late-onset spinal muscular atrophy, atypical ALS, or
p2950.e2 M. van Blitterswijk et al. / Neurobiology of Aging 33 (2012) 2950.e1–2950.e4typical ALS (Nishimura et al., 2004). Moreover, several
patients were also described with autonomic abnormalities,
including chronic intestinal constipation, and sexual dys-
function (Marques et al., 2006). Subsequently, this mutation
has been described in patients of Brazilian, Japanese, and
European origin (Funke et al., 2010; Landers et al., 2008;
Millecamps et al., 2010). Recently, a second missense mu-
tation in VAPB (p.T46I) was identified in a cohort of FALS
patients from the United Kingdom (Chen et al., 2010). We
investigated the mutation frequency of VAPB mutations in a
well-genotyped cohort of ALS patients and control subjects
of Dutch descent.
2. Methods
The study population consisted of 755 patients with
sporadic ALS (SALS) and 111 patients with FALS (from 97
different families). All patients were seen at national referral
centers for neuromuscular diseases (University Medical
Center Utrecht, Academic Medical Center, Amsterdam, and
Radboud University Nijmegen Medical Center) and diag-
nosed with ALS according to the El Escorial criteria
(Brooks et al., 2000). Their baseline characteristics are
shown in Supplementary Table 1. We also included 765
control subjects of Dutch descent. Patient material was
obtained with approval of the Institutional Review Board,
and participants gave informed consent. All FALS patients,
and large cohorts of SALS patients and control subjects, had
been screened for mutations in TARDBP, FUS/TLS, SOD1,
ANG, and C9orf72 (van Blitterswijk et al., 2012).
We screened coding regions of VAPB (NM_004738) for
mutations. Previously described primers were used for am-
plification by touchdown polymerase chain reaction (Chen
et al., 2010). For sequencing and data analysis BigDye
Terminator 3.1 sequencing kit (Applied Biosystems, Foster
City, CA, USA), DNA Analyzer 3730XL (Applied Biosys-
tems), and PolyPhred were used (Nickerson et al., 1997).
We confirmed mutations on genomic DNA, and used Poly-
Phen-2 to predict the impact of these mutations on the
structure and function of VAPB (genetics.bwh.harvard.edu/
Table 1
Variants found in VAPB
Variant Exon FALS families (n  97)
p.A104T 3 0 (0.0%)
p.D130Ea 4 0 (0.0%)
p.S158N 5 1 (1.0%)
p.S160dela 5 1 (1.0%)
p.M170I 5 0 (0.0%)
p.V234I 6 1 (1.0%)b
Total 3 (3.1%)
The impact of missense variants on the structure, and func
harvard.edu/pph2/). One of the variants, p.V234I, is likely to be pathogen
Key: CON, control subjects; FALS, familial amyotrophic lateral sclerosis
a The p.S160del and p.D130E variants have been reported previously; b
et al., 2008).b This patient also has a C9orf72 repeat expansion.pph2/; version 2.1.0, released May 2011). PolyPhen-2 val-
ues were also used for the variable-threshold test to analyze
grouped mutations (Price et al., 2010). This statistical test
increases statistical power, and uses a threshold that sepa-
rates mutations that are likely to be detrimental or nondet-
rimental. The program R was used to perform this statistical
analysis (CRAN; www.r-project.org).
3. Results
In our Dutch cohort we identified VAPB variants in 3.1%
of the FALS families, 1.5% of the SALS patients, and 1.4%
of the control subjects (Table 1). Only 1 of these variants,
p.V234I, had not been detected in control subjects (1.0% of
FALS). The variable-threshold test displayed that there was
no significant difference in mutational burden between pa-
tients and control subjects, no matter whether we took
potential damaging effects of mutations into account (p 
0.49) or not (p  0.53).
We used PolyPhen-2 to predict the effects of these VAPB
variants, and demonstrated that p.S158N and p.V234I could
have damaging effects (Table 1). Because p.S158N was also
detected in 1 control subject, this variant most likely repre-
sents a benign rare polymorphism; p.V234I, on the other
hand, was not detected in control subjects. The pathogenic-
ity estimate of the p.V234I mutation was 0.79 (values above
0.50 indicate pathogenicity) with a sensitivity of 0.85 and
specificity of 0.93. Moreover, it is located in a region that is
highly conserved across species, and appears to cause small
changes to -helixes located within the VAPB protein (Sup-
lementary Fig. 1). This VAPB mutation was detected in a
patient that also harbored a C9orf72 repeat expansion (Sup-
plementary Fig. 1). She developed weakness in her right leg
at 65 years of age, without signs of frontotemporal dementia
(FTD), and died after 34 months (Supplementary Table 2).
Her mother, uncle, and grandmother had also died of ALS
(Supplementary Fig. 2). None of her family members had
been diagnosed with FTD.
(n  755) CON (n  765) Prediction PolyPhen-2
0%) 1 (0.1%) Benign
1%) 0 (0.0%) Benign
0%) 1 (0.1%) Possibly damaging
7%) 4 (0.5%) Not applicable
7%) 5 (0.7%) Benign
0%) 0 (0.0%) Possibly damaging
5%) 11 (1.4%)
of the protein was predicted with PolyPhen-2 (genetics.bwh.
is denoted by the bold font.
, sporadic amyotrophic lateral sclerosis.
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Our study identified 1 novel VAPB mutation (p.V234I)
that was absent in control subjects, located in a region with
high evolutionary conservation, and predicted to be patho-
genic. Currently, only 2 pathogenic VAPB mutations have
been reported. The first mutation, p.P56S, was identified in
motor neuron disease families with phenotypic heterogene-
ity (Nishimura et al., 2004). The second mutation, p.T46I,
was recently detected in 1 FALS patient from the United
Kingdom (Chen et al., 2010). VAPB has 3 conserved do-
mains: an N-terminal immunoglobulin-like -sheet that re-
sembles the nematode major sperm protein (amino acid
1–125) and contains a double phenylalanine in an acidic
tract, a central coiled–coil domain (amino acid 158–211),
and a C-terminal transmembrane domain (amino acids 220–
243) (Lev et al., 2008). The p.P56S, and p.T46I mutations
are both located within the nematode major sperm protein;
the p.V234I mutation is located in the transmembrane do-
main. VAPB is known to be involved in many cellular
processes, including lipid metabolism, membrane traffick-
ing, the unfolded protein response, microtubule organiza-
tion, and homeostatic- and stress-signaling systems in the
endoplasmic reticulum (ER) (Gkogkas et al., 2008;
Kanekura et al., 2009; Lev et al., 2008). Mutations in VAPB
ave already been shown to cause cytoplasmic transactive
esponse DNA-binding protein 43 (TDP-43) accumulations,
ead to ER disorganization, and increase the vulnerability of
otor neuron cells to ER stress-induced death (Chen et al.,
010; Tudor et al., 2010).
The identified p.V234I mutation was present in 1 FALS
atient, which also harbored a C9orf72 repeat expansion.
This repeat expansion has recently been identified as the
most common genetic cause of ALS (Dejesus-Hernandez et
al., 2011; Renton et al., 2011). We have already reported
that C9orf72 repeat expansions can be detected in approx-
imately 37% of the FALS families in The Netherlands (van
Rheenen et al., 2012). In addition, we have shown that these
repeat expansions can be identified in FALS patients with
TARDBP (p.N352S), FUS/TLS (p.Q210H), or SOD1
p.D90A) mutations (van Blitterswijk et al., 2012). A recent
tudy in Sardinia also reported C9orf72 repeat expansions in
atients with TARDBP (p.A382T) mutations (Chiò et al.,
012). One of their patients had ALS and FTD, his age at
nset was 43 years, his disease duration was 34 months, and
oth his parents had also been diagnosed with ALS and
TD. Furthermore, they described another patient that de-
eloped ALS without FTD at 35 years of age; this patient
as tracheotomized after 25 months, and none of his family
embers was known to have ALS or FTD (reduced pen-
trance). They argued that the age at symptom onset was
nfluenced by the genetic burden of the individual, and that
hese patients demonstrated a relatively severe disease
ourse. We, however, could not detect significant differ-
nces in age at onset between patients with mutations in 1LS-associated gene and patients with mutations in multi-
le ALS-associated genes (van Blitterswijk et al., 2012).
he detection of mutations in multiple ALS-associated
enes, and their detection in families with reduced pen-
trance and/or apparently sporadic patients (Chiò et al.,
012; van Blitterswijk et al., 2012), does suggest that the
tiology of ALS is more complex than previously thought.
In our present study, we report a novel VAPB mutation in
patient with a C9orf72 repeat expansion. This repeat
xpansion has been reported in patients with a range of
linical phenotypes, including FTD, ALS, ALS-FTD, and
rogressive muscular atrophy (Dejesus-Hernandez et al.,
011; Renton et al., 2011; van Rheenen et al., 2012). VAPB
utations have been detected in patients with phenotypic
eterogeneity as well (Nishimura et al., 2004). We, there-
ore, hypothesize that these phenotypic differences can be
ttributed to interactions between ALS-associated genes,
hus emphasizing the complex oligogenic etiology of neu-
odegenerative diseases, and of ALS in particular.
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